Apparently in the US and most of Europe, Sanofi are withdrawing the unlicensed use of Campath for MS treatment ie use outside of a recognised trial. Drs. will only be able to get it for named cancer patients. I think this starts in the US in November. This is in preparation for it to be licensed under Lemtrada once the EMA and FDA have looked at it.